Assessment of depression in patients with chronic viral hepatitis: Effect of interferon treatment

Digestive Diseases

Volumn 20, Issue 3-4, 2002, Pages 284-288

  Koskinas, J ^a   Merkouraki, P ^a   Manesis, E ^a   Hadziyannis, Stephanos ^a,b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Adverse effects; Chronic viral hepatitis; Depression; Interferon

Indexed keywords

ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; VIRUS HEPATITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DEPRESSION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUESTIONNAIRES; RIBAVIRIN;

EID: 0036965364     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067682     Document Type: Article

References (32)

1. Alter MJ: Epidemiology of hepatitis C. Hepatology 1997;26(suppl 1):62S-65S.
2. Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995;332:1463-1466.
3. Hadziyannis SJ: Hepatitis B e antigen negative chronic hepatitis B: From clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev 1995;1:7-36.
4. Davis GL, Esteban Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-1499.
5. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J: Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodmann ZD, Koury K, Ling M, Albrecht J: Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
8. Niederau G, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D: Long term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
9. Tine F, Liberati A, Graxi A, Almasio P, Pagliaro L: Interferon treatment in patients with chronic hepatitis B: A meta-analysis of the published literature. J Hepatol 1993;18:154-163.
10. Wong JB, Koff RS, Tine F, Pauker SG: Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-675.
11. Lin S, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999;29:971-975.
12. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
13. Dusheiko B: Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997;26(suppl 1):112S-121S.
14. Janssen HLA, Brouwer JT, Van Der Mast RC, Schalm SW: Suicide associated with alpha interferon therapy for chronic viral hepatitis. J Hepatol 1994;21:241-243.
15. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C, Clemens J: Suicidal ideation with interferon alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2002;43:88.
16. Zung WWK: The puzzle of depression diagnoses: A binomial solution; in Cavenaz JO, Brodie HKH (eds): Critical Problems in Psychiatry. Philadelphia, Lippincott, 1982, pp 157-179.
17. Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70.
18. Arve S, Lauri S, Lehtonen A: Clinical pathway of elderly persons with lowered mood in the health care services. Scand J Caring Sci 2000;14:191-198.
19. Deyo R, Patrick D: Barriers to the use of health status measures in clinical investigation, patient care and policy research. Med Care 1989;27:254S-268S.
20. Pariante CM, Orru MC, Baita A, Farci MG, Carpiniello A: Treatment with interferon-α in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354:131-132.
21. Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology 1999;30:550-555.
22. Younnosi ZB: Economic and quality-of-life measures in the study of viral hepatitis. Viral Hepatitis Rev 1999;5:101-111.
23. Younossi ZM, Boparai N, McCormick M, Price LL, Guyatt G: Assessment of utilities and health-related quality of life in patients with chronic liver disease. Am J Gastroenterol 2001;96:579-583.
24. Bonkovsky HL, Woolley JM, and the Consensus Interferon Study Group: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-270.
25. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998;27:209-212.
26. Ware JA, Davis GL: Health related quality of life in chronic hepatitis C. Impact of disease and treatment response. Hepatology 1999;30:550-555.
27. Fontana RJ, Moyer CA, Sonnad S, Lok ASF, Sneed-Pee N, Walsh J, Klein S, Webster S: Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol 2001;96:174-177.
28. Neary MP, Cort S, Bayliss MS, Ware JE: Sustained virologic response is associated with improved health related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999;19:77-85.
29. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996;24:778-779.
30. Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, Redaelli A, Roffi L, Mancia G: Depression during interferon therapy for chronic viral hepatitis: Early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000;12:505-509.
31. Diepering E, Willenbring ML, Tetrick L, et al: Prospective evaluation of neuropsychiatric symptoms in patients with hepatitis C treated with interferon-alpha-2b and ribavirin (abstract). Gastroenterology 2002;122:T1412.
32. Ware JE, Snow KK, Kosinski M, Gandek B (eds): SF-36 Health Survey Manual and Interpretation Guide. Boston, New England Medical Center and Health Institute, 1993.